1 Myelofibrosis: Executive Summary
1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology
2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 8MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Diagnosed incident cases of PMF
2.4.4 Diagnosed incident cases of PET MF and PPV MF
2.4.5 MIPSS70+ V2.0 risk categories among diagnosed PMF incident cases
2.4.6 Mutations among the diagnosed incident cases of PMF
2.4.7 Patients with/without anemia among the diagnosed incident cases of PMF
2.4.8 Diagnosed prevalent cases of PMF
2.4.9 Diagnosed prevalent cases of PET MF and PPV MF
2.5 Epidemiological forecast of myelofibrosis (2021-31)
2.5.1 Diagnosed incident cases of PMF
2.5.2 Age-specific diagnosed incident cases of PMF
2.5.3 Sex-specific diagnosed incident cases of PMF
2.5.4 Diagnosed incident cases of PMF by MIPSS70+ V2.0 risk category
2.5.5 Diagnosed incident cases of PMF by mutation
2.5.6 Patients with or without anemia among diagnosed incident cases of PMF
2.5.7 Diagnosed incident cases of PET MF
2.5.8 Sex-specific diagnosed incident cases of PET MF
2.5.9 Diagnosed incident cases of PPV MF
2.5.10 Sex-specific diagnosed incident cases of PPV MF
2.5.11 Diagnosed prevalent cases of PMF
2.5.12 Age-specific diagnosed prevalent cases of PMF
2.5.13 Sex-specific diagnosed prevalent cases of PMF
2.5.14 Diagnosed prevalent cases of PET MF
2.5.15 Sex-specific diagnosed prevalent cases of PET MF
2.5.16 Diagnosed prevalent cases of PPV MF
2.5.17 Sex-specific diagnosed prevalent cases of PPV MF
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
Contact Us

List of Tables
Table 1: Summary of changes to data types and countries
Table 2: Summary of updated data types
Table 3: Risk factors and comorbid conditions associated with MF
Table 4: 8MM, diagnosed incident cases of PMF by MIPSS70+ v2.0 risk category, N, men and women, ages ?40 years, 2021

List of Figures
Figure 1: 8MM, diagnosed incident cases of MF, both sexes, N, ages ?40 years, 2021 and 2031
Figure 2: 8MM, diagnosed prevalent cases of MF, both sexes, N, ages ?40 years, 2021 and 2031
Figure 3: 8MM, diagnosed incidence of PMF (cases per 100,000 population), men and women, ages ?40 years, 2021
Figure 4: 8MM, diagnosed prevalence of PMF (%), men and women, ages ?40 years, 2021
Figure 5: 8MM, sources used and not used to forecast the diagnosed incident cases of PMF
Figure 6: 8MM, sources used to forecast the diagnosed incident cases of PET MF and PPV MF
Figure 7: 8MM, sources used to forecast the diagnosed incident cases of PMF by MIPSS70+ v2.0 risk categories
Figure 8: 8MM, sources used to forecast the diagnosed incident cases of PMF by JAK2V617F mutation
Figure 9: 8MM, sources used to forecast the diagnosed incident cases of PMF by CALR mutation
Figure 10: 8MM, sources used to forecast the diagnosed incident cases of PMF by MPL mutation
Figure 11: 8MM, sources used to forecast the diagnosed incident cases of PMF by anemia
Figure 12: 8MM, sources used to forecast the diagnosed prevalent cases of PMF
Figure 13: 8MM, sources used to forecast the diagnosed prevalent cases of PET MF and PPV MF
Figure 14: 8MM, diagnosed incident cases of PMF, N, men and women, ages ?40 years, 2021
Figure 15: 8MM, diagnosed incident cases of PMF by age, N, men and women, 2021
Figure 16: 8MM, diagnosed incident cases of PMF by sex, N, ages ?40 years, 2021
Figure 17: 8MM, diagnosed incident cases of PMF by mutation, N, men and women, ages ?40 years, 2021
Figure 18: 8MM, patients with or without anemia among diagnosed incident cases of PMF, N, men and women, ages ?40 years, 2021
Figure 19: 8MM, diagnosed prevalent cases of PET MF, N, men and women, ages ?40 years, 2021
Figure 20: 8MM, diagnosed incident cases of PET MF by sex, N, ages ?40 years, 2021
Figure 21: 8MM, diagnosed prevalent cases of PPV MF, N, men and women, ages ?40 years, 2021
Figure 22: 8MM, diagnosed incident cases of PPV MF by sex, N, ages ?40 years, 2021
Figure 23: 8MM, diagnosed prevalent cases of PMF, N, men and women, ages ?40 years, 2021
Figure 24: 8MM, diagnosed prevalent cases of PMF by age, N, men and women, 2021
Figure 25: 8MM, diagnosed prevalent cases of PMF by sex, N, ages ?40 years, 2021
Figure 26: 8MM, diagnosed prevalent cases of PET MF, N, men and women, ages ?40 years, 2021
Figure 27: 8MM, diagnosed prevalent cases of PET MF by sex, N, ages ?40 years, 2021
Figure 28: 8MM, diagnosed prevalent cases of PPV MF, N, men and women, ages ?40 years, 2021
Figure 29: 8MM, diagnosed prevalent cases of PPV MF by sex, N, ages ?40 years, 2021